Tests a folate supplement in pregnant people with high blood pressure
Tests a folate supplement against a placebo in pregnant adults with high blood pressure.
Key facts
- Who runs it
- University of Oxford
- Where
- Oxford, United KingdomSee the 2 sites
- Trial code
- Registry title
- Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies
- Status
- Recruiting
- People taking part
- 128 people, planned
- Started
- 1 Jun 2021
- Planned end
- Oct 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Arcofolin® 5-Methyltetrahydrofolate
- Arcofolin® Placebo
- Record updated
- 29 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women, either with pre-eclampsia before 34 weeks or with normal blood pressure. It studies a folate supplement and blood vessel function.
- Age
- Over 18 and up to 45 years
- Sex
- Women only
- Disease stage
- Pre-eclampsia group: diagnosed at less than 34 weeks of pregnancy within the last 48 hours, with no birth planned within the next week. Comparison group: normal blood pressure (below 140/90) throughout pregnancy.
- Earlier treatment
- Pre-eclampsia group: no folate supplement above 400mcg in the third trimester, and no proton pump inhibitors or anti-epileptic drugs. Comparison group: no beta blockers such as atenolol or equivalent.
- Biomarker or test result
- Comparison group: SFlt/PIGF ratio below 35. Both groups: vitamin B12 level not below 148 pmol/L (pre-eclampsia group).
Main reasons for not taking part
- Heart problems such as uncontrolled arrhythmia, unstable angina, heart failure or valve disease
- Existing long-term kidney disease
- Baby with any known trisomy, a congenital heart defect, a known infection or high risk of heart disease
- Known severe anaemia in the baby
- Cannot take folate supplements (pre-eclampsia group)
This trial only enrols pregnant participants. The registry sentence this rests on: Normotensive, blood pressures <140/90 throughout antenatal period
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Diagnosed with preeclampsia, as defined in Section 8.1, at <34 weeks' gestation within the last 48 hours and with no delivery planned within the next week
- Receiving antenatal care in the John Radcliffe Hospital
- Participant is willing and able to give informed consent for participation in the study
- Age >18 and ≤45 years
- Participant is willing and able to give informed consent for participation in the study
- Age >18 and ≤45 years
- Normotensive, blood pressures <140/90 throughout antenatal period
- Less than 2 moderate risk factors for hypertensive disease in pregnancy according to the NICE guideline for management of hypertension in pregnancy
- SFlt/PIGF ratio <35
Who cannot take part
- Intake of either proton pump inhibitors or anti-epileptic drugs
- History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease
- History of preexisting chronic renal disease
- Fetus with congenital heart defect
- Fetus at a high risk of heart disease
- Known infection of fetus
- Diagnosis of hypertensive disorder of pregnancy
- History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease
- History of preexisting chronic renal disease Fetal
- Fetus with congenital heart defect
- Fetus at a high risk of heart disease
- Known infection of fetus
- The participant may not enter the study if ANY of the following apply:
- Maternal
- Contraindication to taking folate related supplements
- Folate supplementation in excess of 400mcg in the third trimester
- Low vitamin B12 levels (<148 pmol/L)
- Organ dysfunction Fetal
- Any known trisomy
- Known severe anaemia
- The participant may not enter the study if ANY of the following apply:
- Maternal
- Use of beta blockers such as atenolol or equivalent
- Any known trisomy
- Known severe anaemia
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Where in United Kingdom
- Cardiovascular Clinical Research FacilityOxford, United KingdomContact: Yvonne KenworthyTaking people
- Oxford University Hospitals NHS Foundation TrustOxford, United KingdomContact: Yvonne KenworthyTaking people
About the trial
What the trial wants to find out
Study background
Read full original descriptionShow less
High blood pressure during pregnancy is a worldwide health problem that can be dangerous to mothers and commonly causes premature birth and small babies. There is also growing evidence that mothers who suffer from high blood pressure in pregnancy, and their babies, have a higher risk of high blood pressure and cardiovascular disease later in life. Previous studies have revealed detrimental changes in the structure and function of the heart and blood vessels of mothers, and their babies, who experience this common complication. These changes may explain their increased risk of later disease. The investigators have also learned through previous studies that tetrahydrobiopterin (BH4), a molecule that has a role in blood vessel health, plays an important role in stabilising blood vessel function. Lower levels of BH4 are evident in both the placenta and the umbilical cord from mothers with high blood pressure. We, therefore, want to investigate how closely BH4 levels are related to clinical features of pre-eclampsia and whether altering levels of BH4, using a nutritional supplement, improves features of the disease such as blood vessel function. To do this, the investigators need to compare the levels of BH4 between mothers with pre-eclampsia, those taking the supplement and those without pre-eclampsia. The investigators also compare how the heart and blood vessels look and function in these groups using ultrasound methods, including echocardiography and fetal sonography.
Study objectives
CAREFOL-HT will assess how levels of BH4 differ in pregnant women with high blood pressure and if this is reflected in functional changes in the heart and blood vessels of these women. The investigators will also determine whether changing levels of BH4, using a tetrahydrofolate supplement (5-MTHF), changes blood vessel function.
The 4 groups in the trial
- NormotensiveNo study treatment, for comparison
A sub-cohort of 32 normotensive women will be recruited to establish normal pregnancy values for the measures performed as well as validation of outcome measures.
- Preeclampsia - PlaceboPlacebo, for comparison
A sub-cohort of 32 preeclampsia women will be recruited taking the placebo.
Treatment: Arcofolin® Placebo
- Preeclampsia - low dosageExisting treatment, for comparison
A sub-cohort of 32 preeclampsia women will be recruited taking the placebo low dose of 5-MTHF.
Treatment: Arcofolin® 5-Methyltetrahydrofolate
- Preeclampsia - high dosageExisting treatment, for comparison
A sub-cohort of 32 preeclampsia women will be recruited taking the placebo high dose of 5-MTHF.
Treatment: Arcofolin® 5-Methyltetrahydrofolate
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies (CAREFOL-HT)
- Plain-language title
- Tests a folate supplement in pregnant people with high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05434195, who can take part
- Publications
- Retinal Vascular Caliber: 6 to 12 Months and 15 to 25 Years Following Hypertensive Pregnancy.Hypertension (Dallas, Tex. : 1979), 2026
- Subclinical Postpartum Renal Structure After Hypertensive Pregnancy Disorders.Hypertension (Dallas, Tex. : 1979), 2025
- Record updated
- 29 April 2026